Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Spectrum Pharma Inc (SPPI)

Spectrum Pharma Inc (SPPI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 358,721
  • Shares Outstanding, K 116,468
  • Annual Sales, $ 0 K
  • Annual Income, $ -112,690 K
  • 60-Month Beta 2.06
  • Price/Sales -286.98
  • Price/Cash Flow N/A
  • Price/Book 2.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.34
  • Number of Estimates 3
  • High Estimate -0.25
  • Low Estimate -0.39
  • Prior Year -0.26
  • Growth Rate Est. (year over year) -30.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.68 +14.93%
on 05/11/20
3.44 -10.47%
on 05/18/20
+0.23 (+8.07%)
since 05/05/20
3-Month
1.74 +76.79%
on 03/19/20
3.44 -10.47%
on 05/18/20
+0.13 (+4.41%)
since 03/05/20
52-Week
1.74 +76.79%
on 03/19/20
10.57 -70.86%
on 12/11/19
-5.07 (-62.21%)
since 06/05/19

Most Recent Stories

More News
Why Is Spectrum Pharma (SPPI) Up 6.6% Since Last Earnings Report?

Spectrum Pharma (SPPI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

SPPI : 3.08 (+3.70%)
Spectrum Pharmaceuticals Appoints Lyndah K. Dreiling, M.D., MBA, as Senior Vice President, Clinical Development

Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that Lyndah K. Dreiling, M.D., MBA, has been named Senior...

SPPI : 3.08 (+3.70%)
Spectrum Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference 2020

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business...

SPPI : 3.08 (+3.70%)
Catalyst (CPRX) Q1 Earnings Beat Estimates, Revenues Miss

Catalyst (CPRX) beats on Q1 earnings but misses on revenues. It also withdraws sales guidance due to the coronavirus pandemic.

SPPI : 3.08 (+3.70%)
CNCE : 9.39 (+4.22%)
TTPH : 2.45 (+15.02%)
CPRX : 4.49 (+3.58%)
Spectrum Pharma (SPPI) Incurs Wider-Than-Expected Q1 Loss

Spectrum Pharma (SPPI) misses bottom-line estimates for the first quarter and records no revenues.

AZN : 53.85 (-0.04%)
SPPI : 3.08 (+3.70%)
IMMU : 30.68 (+1.67%)
SGEN : 148.39 (-1.36%)
Lymphoma Treatment Market to Register a CAGR of 8.3%; Increasing R&D Investments by Key Players to Augment Growth, sates Fortune Business Insights(TM)

The global lymphoma treatment market size is predicted to reach USD 13.11 billion by 2026, exhibiting a CAGR of 8.3% during the forecast period. The increasing R&D investments for strong pipeline candidates...

AGIO : 50.66 (+2.20%)
GILD : 76.75 (-1.02%)
KITE : 179.99 (+0.11%)
NVS : 85.89 (+0.90%)
SPPI : 3.08 (+3.70%)
TEVA : 12.84 (+0.71%)
Spectrum Pharma: 1Q Earnings Snapshot

HENDERSON, Nev. (AP) _ Spectrum Pharmaceuticals Inc. (SPPI) on Thursday reported a loss of $40.6 million in its first quarter.

SPPI : 3.08 (+3.70%)
Spectrum Pharmaceuticals Reports First Quarter 2020 Financial Results and Pipeline Update

--ROLONTIS same day dosing study initiated

SPPI : 3.08 (+3.70%)
Cancer Monoclonal Antibodies Industry, Forecast to 2025 - Data on Bevacizumab, Rituximab, Trastuzumab, Cetuximab, Panitumumab and Others

, /PRNewswire/ -- The report has been added to offering.

ABBV : 93.85 (+0.87%)
AMGN : 225.67 (+2.17%)
BMY : 61.33 (+0.72%)
LLY : 149.21 (-1.00%)
GNMSF : 288.5400 (+1.05%)
GSK : 41.70 (+0.12%)
MRK : 82.26 (+0.87%)
NVS : 85.89 (+0.90%)
PFE : 35.99 (-0.06%)
RHHBY : 42.9500 (-0.81%)
SGEN : 148.39 (-1.36%)
SPPI : 3.08 (+3.70%)
Spectrum Pharmaceuticals to Report First Quarter 2020 Financial Results and Provide Corporate Update

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the first quarter 2020...

SPPI : 3.08 (+3.70%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Trade SPPI with:

Business Summary

Spectrum Pharmaceuticals, Inc. is opportunistically acquiring and advancing a diversified portfolio of oncology drug candidates that meet critical health challenges for which there are few other treatment options. Spectrum's expertise lies in identifying undervalued drugs with demonstrated safety and...

See More

Key Turning Points

2nd Resistance Point 3.19
1st Resistance Point 3.14
Last Price 3.08
1st Support Level 3.00
2nd Support Level 2.92

See More

52-Week High 10.57
Fibonacci 61.8% 7.20
Fibonacci 50% 6.16
Fibonacci 38.2% 5.11
Last Price 3.08
52-Week Low 1.74

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar